PMID: 3755347Aug 1, 1986Paper

Clinical pharmacology of atracurium given in high dose

British Journal of Anaesthesia
R P ScottD C Hoaglin

Abstract

The safety and efficacy of atracurium 0.8 mg kg-1 was determined in healthy patients with particular attention to the speed of onset of blockade, and to changes in haemodynamic variables. Atracurium 0.8 mg kg-1 had a shorter onset time than atracurium 0.5 mg kg-1, and satisfactory intubating conditions were achieved earlier. "Priming" produced no significant improvement in onset time or intubating conditions. Onset times were significantly shorter with nitrous oxide-opioid anaesthesia than following thiopentone alone. Although a 0.8-mg kg-1 bolus resulted in a significant reduction in mean arterial pressure to 75% of control and was associated with a significant increase in plasma histamine concentrations, this response could be prevented by injecting the drug over 75 s. "Priming" or a 30-s injection produced no haemodynamic protection. The protection achieved by pretreatment with anti-histamines was incomplete: mean arterial pressure decreased to 83% of control.

Citations

Sep 1, 1996·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·L S BluesteinR M Wilson
Mar 1, 1987·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·M E McLeod, J Lerman
Aug 1, 1994·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·K F Koh, F G Chen
Feb 4, 2005·Regional Anesthesia and Pain Medicine·Régis Fuzier, François Singelyn
Jul 1, 1993·Anaesthesia·G D ShortenH H Ali
Jan 1, 1995·Acta Anaesthesiologica Scandinavica. Supplementum·J J Savarese, W B Wastila
Jan 1, 1993·Intensive Care Medicine·M J MurrayC Weiler
Oct 1, 1991·Journal of Cardiothoracic and Vascular Anesthesia·M A WarnerT A Orszulak
Mar 1, 1992·Journal of Clinical Anesthesia·S J Basta
Jan 1, 1992·Journal of Clinical Anesthesia·D G SilvermanS J Brull
Jun 1, 1989·Anaesthesia·A J CharltonA C Wilson
Feb 22, 2012·Physics in Medicine and Biology·Muyinatu A Lediju BellJeffrey C Bamber
Mar 17, 2020·Journal of Anaesthesiology, Clinical Pharmacology·Pornpan ChalermkitpanitSireedhorn Assavanop
Jan 1, 1991·DICP : the Annals of Pharmacotherapy·G E LarijaniA G Jacobi
Aug 24, 2021·Frontiers in Immunology·Benjamin D McNeil

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.